The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AXL and CDCP1: A roadmap of innate resistance in EGFR mutant NSCLC.
 
Niki Karachaliou
No Relationships to Disclose
 
Imane Chaib
No Relationships to Disclose
 
Andres Felipe Cardona Zorrilla
No Relationships to Disclose
 
Jordi Berenguer
No Relationships to Disclose
 
Jillian Bracht
No Relationships to Disclose
 
Jie Yang
No Relationships to Disclose
 
Xueting Cai
No Relationships to Disclose
 
Zhigang Wang
No Relationships to Disclose
 
Ana Drozdowskyj
No Relationships to Disclose
 
Ilaria Attili
No Relationships to Disclose
 
July Katherine Rodríguez
No Relationships to Disclose
 
Luis Leonardo Rojas Puentes
No Relationships to Disclose
 
Santiago Viteri Ramirez
No Relationships to Disclose
 
Sai-Hong Ignatius Ou
Stock and Other Ownership Interests - TP Therapeutics
Honoraria - ARIAD/Takeda; AstraZeneca; Foundation Medicine; Genentech/Roche; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Foundation Medicine; Ignyta; Novartis; Pfizer; Roche/Genentech; Takeda; TP Therapeutics
Speakers' Bureau - AstraZeneca; Genentech; Takeda
Research Funding - ARIAD (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); Roche Pharma AG (Inst)
 
Tony Mok
Employment - The Chinese University of Hong Kong
Leadership - Sanomics Limited
Stock and Other Ownership Interests - Cirina; Sanomics Limited
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ACEA Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Cirina; Clovis Oncology; geneDecode; Ignyta; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Oncogenex; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Taiho Pharmaceutical (Inst)
 
Trever Grant Bivona
No Relationships to Disclose
 
Mayumi Ono
No Relationships to Disclose
 
Jingrong Jean Cui
No Relationships to Disclose
 
Peng Cao
No Relationships to Disclose
 
Rafael Rosell
No Relationships to Disclose